A003520 Stock Overview
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Yungjin Pharm. Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩2,070.00 |
52 Week High | ₩3,085.00 |
52 Week Low | ₩1,960.00 |
Beta | 0 |
1 Month Change | -5.05% |
3 Month Change | 1.47% |
1 Year Change | -29.71% |
3 Year Change | -68.25% |
5 Year Change | -68.45% |
Change since IPO | -96.36% |
Recent News & Updates
Recent updates
Shareholder Returns
A003520 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 2.2% | 3.9% | 0.5% |
1Y | -29.7% | 8.3% | 4.7% |
Return vs Industry: A003520 underperformed the KR Pharmaceuticals industry which returned 8.3% over the past year.
Return vs Market: A003520 underperformed the KR Market which returned 4.7% over the past year.
Price Volatility
A003520 volatility | |
---|---|
A003520 Average Weekly Movement | 3.0% |
Pharmaceuticals Industry Average Movement | 4.6% |
Market Average Movement | 5.3% |
10% most volatile stocks in KR Market | 11.8% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A003520 has not had significant price volatility in the past 3 months.
Volatility Over Time: A003520's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1952 | n/a | Chae-Joon Lee | www.yungjin.co.kr |
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. The company also provides vitamins, minerals, and other products; and APIs.
Yungjin Pharm. Co., Ltd. Fundamentals Summary
A003520 fundamental statistics | |
---|---|
Market cap | ₩378.59b |
Earnings (TTM) | ₩8.53b |
Revenue (TTM) | ₩158.79b |
0.0x
P/E Ratio0.0x
P/S RatioIs A003520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A003520 income statement (TTM) | |
---|---|
Revenue | ₩158.79b |
Cost of Revenue | ₩99.50b |
Gross Profit | ₩59.28b |
Other Expenses | ₩50.76b |
Earnings | ₩8.53b |
Last Reported Earnings
Sep 30, 2013
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A003520 perform over the long term?
See historical performance and comparison